Atara Biotherapeutics (ATRA) came out with a quarterly loss of $3.10 per share versus the Zacks Consensus Estimate of a loss of $1.25. This compares to loss of $17 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -148%. A quarter ago, it was expected that this drug developer would post a loss of $9.25 per share when it actually produced a loss of $5.75, delivering a surprise of 37.84%.Over the last four quarters, the company ha ...